Other grades of this product :
| Product Name: | NNMTi | | Synonyms: | 5-amino-1-methylquinolin-1-ium iodide;5-amino-1MQ;NNMTi;5-Amino-1methylquinolinium iodide;5-Amino-1-methylquinolinium | | CAS: | 42464-96-0 | | MF: | | MW: | 0 | | EINECS: | | Product Categories: | API | | Mol File: | Mol File |
| NNMTi Chemical Properties |
| NNMTi Usage And Synthesis |
| Biological Activity | NNMTi is a potent nicotinamide N-methyltransferase (NNMT) inhibitor (IC50=1.2 μM), selectively binding to NNMT substrate binding site residues. NNMTi can promote myoblast differentiation in vitro and enhance the fusion and regeneration of muscle stem cells in aged mice. | | in vitro | NNMTi (10-30 μM; 96 hours) produces a concentration-related increase in myoblast differentiation on C2C12 myoblast differentiation. 30 μM NNMTi results in 18% MHC-positive myotube nuclei, representing a 45% increase in the extent of myoblast differentiation compared to untreated differentiating myoblasts (12% MHC-positive myotube nuclei). | | in vivo | NNMTi (subcutaneous (SC) injection; 5 mg/kg and 10 mg/kg; 2 weeks (1 week pre-injury and 1 week post-injury)) has an effect on muscle regeneration after injury, it results in 60% and 75% higher incidence of proliferating/active muSCs at 5 mg/kg and 10 mg/kg, respectively. The relative numbers of fibers with an EdU + myonucleus increased 40% and 48% with NNMTi treatment at 5 mg/kg and 10 mg/kg, respectively. The odds ratio of fused myonuclei for control are 0.58 and 0.53 times the odds at the low and high NNMTi dose, respectively.NNMTi (subcutaneous injection; 10 mg/kg; 1 week) produces no systemic toxicity in mice, the levels of the glucose, cholesterol, plasma proteins, and electrolytes between control and NNMTi-treated samples show no difference in mice. 1-week post-injury daily repeat-dosing of NNMTi is well tolerated with no untoward systemic toxicity or behavioral implications in aged mice. |
| NNMTi Preparation Products And Raw materials |
|
日本语
한국어
Français
Deutsch
España
Türkiye